Introduction to Prostap (Leuprorelin Acetate)
Prostap is the brand name for the medication leuprorelin acetate [1.2.1]. It belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) agonists [1.7.3]. As a synthetic version of a naturally occurring hormone, Prostap is a cornerstone of hormone therapy for several conditions that are sensitive to sex hormones like testosterone and oestrogen [1.3.4, 1.7.3]. It is administered as a subcutaneous (under the skin) or intramuscular (into the muscle) injection, with formulations available for monthly, 3-monthly, or 6-monthly doses [1.2.1, 1.6.2, 1.4.1]. This allows for sustained-release action, making the treatment more manageable for patients [1.3.2].
How Does Prostap Work?
The mechanism of Prostap is a fascinating process of hormonal regulation. As a GnRH agonist, it mimics the body's natural gonadotropin-releasing hormone [1.3.2]. When first administered, it binds to receptors in the pituitary gland and causes a temporary surge in the production of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) [1.3.3]. This initial 'flare' can briefly increase testosterone in men or oestrogen in women, sometimes leading to a temporary worsening of symptoms [1.4.4, 1.7.4].
However, with continuous exposure, the pituitary gland becomes desensitized to the GnRH signal [1.3.3]. This downregulation of receptors effectively 'switches off' the production of LH and FSH [1.2.1]. By shutting down these signals, the testicles in men and the ovaries in women dramatically reduce their production of testosterone and oestrogen, respectively [1.3.4]. This state of low sex hormones is often referred to as medical or chemical castration and is the key to Prostap's therapeutic effects [1.3.3].
Primary Medical Uses of Prostap Injections
Prostap's ability to lower sex hormones makes it an effective treatment for several conditions:
- Prostate Cancer: Many prostate cancers rely on testosterone to grow [1.4.4]. By reducing testosterone to castration levels, Prostap can slow or stop the growth of cancer cells, providing palliative treatment for advanced or metastatic prostate cancer [1.3.5]. It is often used as a long-term therapy [1.4.4].
- Endometriosis and Uterine Fibroids: Endometriosis and uterine fibroids are conditions in women where tissue growth is fuelled by oestrogen [1.5.3, 1.7.4]. Prostap creates a temporary, reversible 'artificial menopause' by stopping oestrogen production [1.5.3]. This causes the endometrial tissue and fibroids to shrink, relieving symptoms like pain and heavy bleeding [1.5.3, 1.7.4]. Treatment is typically limited to six months to mitigate long-term side effects like bone density loss [1.10.2].
- Breast Cancer: In premenopausal women with oestrogen receptor-positive (ER-positive) breast cancer, Prostap is used to suppress ovarian function, stopping the production of oestrogen that fuels the cancer [1.2.1]. It is often given in combination with other hormone therapies like tamoxifen or aromatase inhibitors [1.2.1].
- Central Precocious Puberty (CPP): Prostap is used to treat children who start puberty at an unusually early age (before age 9 in girls, age 10 in boys) [1.8.2]. By pausing the hormonal signals that drive puberty, it allows for more normal physical and psychological development until a more appropriate age [1.3.1].
The Treatment Process and What to Expect
Prostap is administered by a doctor or nurse as an injection into the muscle or fatty tissue of the arm, thigh, or abdomen [1.4.3]. The injection site should be rotated regularly to avoid skin reactions [1.4.1]. The dosage and frequency—monthly, every three months, or every six months—depend on the specific formulation (e.g., Prostap SR vs. Prostap 3) and the condition being treated [1.6.2].
Following the first injection, patients may experience a 'tumour flare,' a temporary increase in symptoms due to the initial hormone surge [1.4.4]. For men with prostate cancer, this could mean increased bone pain or urinary issues; for women with endometriosis, pelvic pain may briefly worsen [1.4.4, 1.7.4]. Doctors may prescribe another medication to manage this initial flare [1.4.4]. Within 2 to 4 weeks, hormone levels drop, and symptoms begin to improve [1.3.3, 1.7.1].
Comparison of Common Hormone Therapies
Prostap is one of several GnRH agonists used in treatment. Another common one is Zoladex (goserelin). They share a similar mechanism and side effect profile.
| Feature | Prostap (leuprorelin) | Zoladex (goserelin) |
|---|---|---|
| Mechanism | GnRH Agonist [1.7.3] | GnRH Agonist [1.7.3] |
| Administration | Subcutaneous or intramuscular injection [1.6.2] | Subcutaneous implant/injection [1.11.2] |
| Common Uses | Prostate cancer, endometriosis, fibroids, breast cancer [1.7.3, 1.2.4] | Prostate cancer, endometriosis, breast cancer [1.7.3, 1.11.2] |
| Initial Effect | Can cause a temporary 'tumour flare' [1.4.4] | Can cause a temporary 'tumour flare' [1.11.2] |
Potential Side Effects and Long-Term Considerations
Because Prostap induces a low-hormone state, its side effects are similar to symptoms of menopause in women or andropause in men [1.5.3, 1.4.2].
Common Side Effects in Both Men and Women:
- Hot flushes and sweating [1.4.3]
- Decreased libido (sex drive) [1.5.3]
- Mood changes and depression [1.2.1]
- Tiredness (fatigue) [1.4.3]
- Weight changes [1.2.1]
- Headaches and dizziness [1.2.1, 1.4.3]
- Joint pain [1.2.1]
- Reactions at the injection site (redness, pain, swelling) [1.9.1]
Specific Side Effects in Men:
- Erectile dysfunction [1.9.2]
- Reduction in the size and function of the testes [1.4.3]
- Loss of muscle mass and growth of breast tissue (gynecomastia) [1.4.2]
Specific Side Effects in Women:
- Vaginal dryness [1.5.3]
- Breast tenderness or changes in size [1.4.3]
- Vaginal bleeding, particularly after the first injection [1.2.1]
Long-Term Effects: The most significant long-term risk is thinning of the bones (osteoporosis) due to prolonged low oestrogen or testosterone levels [1.9.2, 1.2.4]. This increases the risk of fractures [1.9.4]. For women on Prostap for gynaecological conditions, treatment is often limited to six months, and 'add-back' Hormone Replacement Therapy (HRT) may be prescribed to counteract bone loss and other menopausal side effects [1.10.2]. Other long-term risks include an increased risk of diabetes and heart problems [1.4.2, 1.9.2].
Conclusion
So, what does Prostap injection do? It acts as a powerful tool in hormone therapy by suppressing the body's production of testosterone and oestrogen. This makes it an effective treatment for hormone-sensitive conditions like prostate cancer, endometriosis, uterine fibroids, and breast cancer. While the side effects can be challenging, they are a direct result of its effective mechanism. For many, Prostap offers significant relief from symptoms and is a crucial part of managing their condition. As with any medication, the benefits and risks should be thoroughly discussed with a healthcare provider.
For more information from a trusted source, you can visit Macmillan Cancer Support.
